These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

821 related articles for article (PubMed ID: 9731217)

  • 21. Detection of antisense and ribozyme accessible sites on native mRNAs: application to NCOA3 mRNA.
    Scherr M; LeBon J; Castanotto D; Cunliffe HE; Meltzer PS; Ganser A; Riggs AD; Rossi JJ
    Mol Ther; 2001 Nov; 4(5):454-60. PubMed ID: 11708882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa.
    Sullivan JM; Pietras KM; Shin BJ; Misasi JN
    Mol Vis; 2002 Apr; 8():102-13. PubMed ID: 11961505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection.
    Tang J; Breaker RR
    RNA; 1997 Aug; 3(8):914-25. PubMed ID: 9257650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A possible advance in arterial gene therapy for aortic complications in the Marfan syndrome by local transfer of an antisense Mg-dependent hammerhead ribozyme.
    Durlach J
    Magnes Res; 2001 Mar; 14(1-2):65-7. PubMed ID: 11300623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel cleavage of a hammerhead ribozyme targeted to beta-amyloid peptide precursor mRNA.
    Denman R; Miller DL
    Arch Biochem Biophys; 1993 Sep; 305(2):392-400. PubMed ID: 8373177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extension of helix II of an HIV-1-directed hammerhead ribozyme with long antisense flanks does not alter kinetic parameters in vitro but causes loss of the inhibitory potential in living cells.
    Homann M; Tabler M; Tzortzakaki S; Sczakiel G
    Nucleic Acids Res; 1994 Sep; 22(19):3951-7. PubMed ID: 7524030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A mutation in FBN1 disrupts profibrillin processing and results in isolated skeletal features of the Marfan syndrome.
    Milewicz DM; Grossfield J; Cao SN; Kielty C; Covitz W; Jewett T
    J Clin Invest; 1995 May; 95(5):2373-8. PubMed ID: 7738200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
    Sun LQ; Wang L; Gerlach WL; Symonds G
    Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of ribozymes that target stathmin, a major regulator of the mitotic spindle.
    Mistry SJ; Benham CJ; Atweh GF
    Antisense Nucleic Acid Drug Dev; 2001 Feb; 11(1):41-9. PubMed ID: 11258620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preferential pre-mRNA utilisation of an upstream cryptic 5' splice site created by a single base deletion mutation in exon 37 of the FBN-1 gene.
    Gibson MA; Ellis SL; Ades LC; Haan E; Cleary EG
    Eur J Biochem; 1998 Aug; 256(1):221-8. PubMed ID: 9746367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A method for prediction of accessible sites on an mRNA sequence for target selection of hammerhead ribozymes.
    Mercatanti A; Rainaldi G; Mariani L; Marangoni R; Citti L
    J Comput Biol; 2002; 9(4):641-53. PubMed ID: 12323098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
    Kronenwett R; Haas R; Sczakiel G
    J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro analysis of a hammerhead ribozyme targeted to infectious bronchitis virus nucleocapsid mRNA.
    Callison SA; Hilt DA; Jackwood MW
    Avian Dis; 2005 Mar; 49(1):159-63. PubMed ID: 15839432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A structural analysis of in vitro catalytic activities of hammerhead ribozymes.
    Shao Y; Wu S; Chan CY; Klapper JR; Schneider E; Ding Y
    BMC Bioinformatics; 2007 Nov; 8():469. PubMed ID: 18053134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of action of hammerhead ribozymes and their applications in vivo: rapid identification of functional genes in the post-genome era by novel hybrid ribozyme libraries.
    Takagi Y; Suyama E; Kawasaki H; Miyagishi M; Taira K
    Biochem Soc Trans; 2002 Nov; 30(Pt 6):1145-9. PubMed ID: 12440992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Towards an RNA-based therapy for Marfan syndrome.
    Kilpatrick MW; Phylactou LA
    Mol Med Today; 1998 Sep; 4(9):376-81. PubMed ID: 9791860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional characterization of ribozymes expressed using U1 and T7 vectors for the intracellular cleavage of ANF mRNA.
    De Young MB; Kincade-Denker J; Boehm CA; Riek RP; Mamone JA; McSwiggen JA; Graham RM
    Biochemistry; 1994 Oct; 33(40):12127-38. PubMed ID: 7918434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intracellular selection of trans-cleaving hammerhead ribozymes.
    Huang X; Zhao Y; Pu Q; Liu G; Peng Y; Wang F; Chen G; Sun M; Du F; Dong J; Cui X; Tang Z; Mo X
    Nucleic Acids Res; 2019 Mar; 47(5):2514-2522. PubMed ID: 30649474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis.
    Werner M; Uhlenbeck OC
    Nucleic Acids Res; 1995 Jun; 23(12):2092-6. PubMed ID: 7610038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and specificity of hammerhead ribozymes against calretinin mRNA.
    Ellis J; Rogers J
    Nucleic Acids Res; 1993 Nov; 21(22):5171-8. PubMed ID: 8255773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.